Alpha Cognition Inc Ordinary Shares ACOG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®
-
Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress
-
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care
-
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update
-
Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update
Trading Information
- Previous Close Price
- $8.30
- Day Range
- $8.30–8.99
- 52-Week Range
- $4.50–10.14
- Bid/Ask
- $8.64 / $9.70
- Shares Outstanding
- 21.78M
- Market Cap
- $194.04M
- Volume/Avg
- 152,589 / 123,110
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.03
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 71
- Website
- https://www.alphacognition.com
Valuation
|
Metric
|
ACOG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.66 |
Price/Sales | 12.03 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ACOG
|
|---|---|
Quick Ratio | 7.33 |
Current Ratio | 9.03 |
Interest Coverage | — |
Quick Ratio
ACOG
Profitability
|
Metric
|
ACOG
|
|---|---|
Return on Assets (Normalized) | −41.17% |
Return on Equity (Normalized) | −52.58% |
Return on Invested Capital (Normalized) | −56.56% |
Return on Assets
ACOG
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|h<#?w> | LOCK|p&%w | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|z###&K> | LOCK|xNg! | $84B | |||
| Moderna Inc
MRNA
| LOCK|&bz&?# | LOCK|Tr | $83B | |||
| argenx SE ADR
ARGX
| LOCK|?&$bf% | LOCK|MFV | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|th@sRff | LOCK|c<T | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Y!&x!^W | LOCK|bZH@ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^!@>@<#< | LOCK|^>VL! | $29B | |||
| Incyte Corp
INCY
| LOCK|jQV!&<! | LOCK|v@% | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|^KCKn#l | LOCK|VV | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|%>?hrk | LOCK|#Vz | $14B |
United States